Case Study

Management Challenge:

• In response to COVID-19 pandemic, a collaborative global endeavor uniting various international health partners to ensure fair and widespread access to vaccines, particularly in underserved regions, formed. This required the client to transition the management approach of its portfolio of COVID-19 assets, from an internal-only portfolio governance committee to a novel muti-partners governance framework in charge of Research and Development and Manufacturing (R&D&M) investment decisions
• Transition aimed to uphold synchronisation with the client's internal governance procedures, while optimising the oversight of the portfolio assets in collaboration with other partners

Project Setup

• Sourced through the network: client executive was an ex-consultant acting as Head of Strategy and Portfolio and needing experienced personnel who could quickly immerse themselves and contribute effectively
• Conducted virtually

Approach & Solution

• Key sponsor: Acting Head of Strategy and Portfolio
• Developed terms of reference and process flows to evolve client's portfolio governance as a result of COVID-19 portfolio transition into the collaborative global endeavor uniting various international health partners
• Designed and implemented adequate cross-functional data flows and tools to ensure accurate and up-to-date muti-partner R&D&M data reporting and enable effective investment committee portfolio decision making 
• Developed and prepared COVID-19 portfolio analyses and insight on an ongoing basis to support timely portfolio decision making
• Ran weekly operations of weekly investment committee 

Benefits & Outcome

• A comprehensive governance architecture which combines oversight and scrutiny of decision making...
• … all the while preserving nimbleness and congruence with the preexisting governance frameworks of both the multi-partners organisation and its respective partners